Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

4(50.0%)

Phase 2

3(37.5%)

Phase 1

1(12.5%)

8Total

Phase 3(4)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02042807Phase 2Active Not Recruiting

To Evaluate the Effect of MCS® in Prostate Cancer Prevention

Role: lead

NCT01016340Phase 2Terminated

Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia

Role: lead

NCT01002664Phase 3Completed

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Role: lead

NCT01002274Phase 3Completed

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

Role: lead

NCT02426216Unknown

Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention

Role: collaborator

NCT01002222Phase 3Completed

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

Role: lead

NCT01002417Phase 2Completed

MCS in the Treatment of Lower Urinary Tract Symptoms

Role: lead

NCT00501371Phase 3Terminated

MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia

Role: lead

NCT01003171Phase 1Unknown

Pharmacokinetics of MCS in Healthy Volunteers

Role: lead

All 9 trials loaded